别名 ESOP-1、ESOP1、Ly-96 + [5] |
简介 Binds bacterial lipopolysaccharide (LPS) (PubMed:17803912, PubMed:17569869). Cooperates with TLR4 in the innate immune response to bacterial lipopolysaccharide (LPS), and with TLR2 in the response to cell wall components from Gram-positive and Gram-negative bacteria (PubMed:11160242, PubMed:11593030). Enhances TLR4-dependent activation of NF-kappa-B (PubMed:10359581). Cells expressing both LY96 and TLR4, but not TLR4 alone, respond to LPS (PubMed:10359581). |
靶点 |
作用机制 LY96抑制剂 [+1] |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2023-08-30 |
申办/合作机构 |
开始日期2023-08-15 |
申办/合作机构- |
开始日期2023-04-05 |
申办/合作机构 |